SAN DIEGO--(BUSINESS WIRE)--This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first ...

Elsewhere, the company's Casgevy, approved some two years ago to treat two rare blood disorders, could also make commercial ...

We think that DexCom stock (NASDAQ NDAQ: DXCM) is currently a better pick than Insulet stock (NASDAQ: PODD), given DexCom’s DXCM better prospects and comparatively lower valuation. DXCM stock trades ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the continuous glucose monitoring (CGM) market. A strong third-quarter 2025 performance and a series ...

As the United States approaches 2026, key structural shifts in retirement and healthcare financing are poised to affect how ...

Diabetes is a global epidemic, with more than 537 million people affected worldwide. DexCom (NASDAQ: DXCM) has improved patient lives with technology, and the stock has outperformed the stock market ...

LONDON, ENGLAND - JUNE 17: Dexcom Warriors Roxy Horner, Adam Smith and Henry Slade host Puppy Yoga to promote mental wellbeing for Diabetes Awareness Week on June 17, 2023 in London, England. (Photo ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

What a brutal six months it’s been for DexCom. The stock has dropped 32.6% and now trades at $58.63, rattling many shareholders. This may have investors wondering how to approach the situation. Given ...

Shares of DexCom recently soared after the company reported better-than-expected third-quarter results. DexCom markets constant blood-glucose monitors for diabetic patients, and its next-generation ...